---
document_datetime: 2025-12-09 23:28:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xelevia.html
document_name: xelevia.html
version: success
processing_time: 0.1534738
conversion_datetime: 2025-12-26 18:52:03.040402
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xelevia

[RSS](/en/individual-human-medicine.xml/66738)

##### Authorised

This medicine is authorised for use in the European Union

sitagliptin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xelevia](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-81435)
- [More information on Xelevia](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Xelevia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xelevia.

Expand section

Collapse section

## What is Xelevia?

Xelevia is a medicine that contains the active substance sitagliptin. It is available as tablets (25, 50 and 100 mg).

## What is Xelevia used for?

Xelevia is used in patients with type-2 diabetes to improve the control of blood glucose (sugar) levels. It is used in addition to diet and exercise in the following ways:

- on its own, in patients who are not satisfactorily controlled on diet and exercise and in whom metformin (an antidiabetes medicine) is not suitable;
- in combination with metformin or a PPAR-gamma agonist (a type of antidiabetes medicine) such as a thiazolidinedione, in patients who are not satisfactorily controlled on metformin or the PPAR-gamma agonist used on its own;
- in combination with a sulphonylurea (another type of antidiabetes medicine) in patients who are not satisfactorily controlled with a sulphonylurea used on its own and in whom metformin is not suitable;
- in combination with both metformin, and a sulphonylurea or a PPAR-gamma agonist, in patients who are not satisfactorily controlled on the two medicines;
- in combination with insulin, with or without metformin, in patients who are not satisfactorily controlled on a stable dose of insulin.

The medicine can only be obtained with a prescription.

## How is Xelevia used?

Xelevia is taken at a dose of 100 mg once a day. If Xelevia is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered to reduce the risk of hypoglycaemia (low blood sugar levels).

In patients with moderately or severely reduced kidney function the dose of Xelevia should be reduced.

## How does Xelevia work?

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Xelevia, sitagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. It works by blocking the breakdown of 'incretin' hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing levels of incretin hormones in the blood, sitagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Sitagliptin does not work when the blood glucose is low. Sitagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Together, these processes reduce blood glucose levels and help to control type-2 diabetes.

## How has Xelevia been studied?

Xelevia was studied in nine studies, involving almost 6,000 patients with type-2 diabetes whose blood glucose levels were not adequately controlled:

- four of the studies compared Xelevia with placebo (a dummy treatment): Xelevia or placebo were used on their own in two studies involving 1,262 patients, as an add-on to metformin in one study involving 701 patients, and as an add-on to pioglitazone (a PPAR-gamma agonist) in one study involving 353 patients;
- two studies compared Xelevia with other antidiabetes medicines. One study compared Xelevia with glipizide (a sulphonylurea), when they were used as an add-on to metformin in 1,172 patients. The other study compared Xelevia with metformin, used on their own, in 1,058 patients;
- three additional studies compared Xelevia with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.

In all of the studies, the main measure of effectiveness was the change in the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.

## What benefit has Xelevia shown during the studies?

Xelevia was more effective than placebo when it was taken alone or in combination with other antidiabetes medicines. In patients taking Xelevia on its own, HbA1c levels fell from around 8.0% at the start of the studies by 0.48% after 18 weeks and 0.61% after 24 weeks. In contrast, they rose by 0.12% and 0.18%, respectively, in the patients taking placebo. Adding Xelevia to metformin reduced HbA1c levels by 0.67% after 24 weeks, compared with a fall of 0.02% in the patients adding placebo. When added to pioglitazone, Xelevia reduced HbA1c levels by 0.85% after 24 weeks, compared with a fall of 0.15% in the patients adding placebo.

In the studies comparing Xelevia with other medicines, the effectiveness of adding Xelevia to metformin was similar to that of adding glipizide. When taken on their own, Xelevia and metformin produced similar reductions in HbA1c levels, but the effectiveness of Xelevia seemed to be slightly lower than that of metformin.

In the additional studies, adding Xelevia to glimepiride (with or without metformin) led to a reduction in HbA1c levels of 0.45% after 24 weeks, compared with an increase of 0.28% in those adding placebo. HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Xelevia to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo. Finally, they were reduced by 0.59% in patients adding Xelevia to insulin (with or without metformin), compared with a fall of 0.03% in those adding placebo.

## What is the risk associated with Xelevia?

Serious side effects reported with Xelevia (generally seen in more than 5% of patients) include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions). Hypoglycaemia has been reported in combination with a sulphonylurea in 4.7-13.8% of patients and with insulin in 9.6% of patients. For the full list of all side effects reported with Xelevia, see the package leaflet.

Xelevia must not be used in people who are hypersensitive (allergic) to sitagliptin or any of the other ingredients.

## Why has Xelevia been approved?

The CHMP decided that Xelevia's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Xelevia

The European Commission granted a marketing authorisation valid throughout the European Union for Xelevia on 21 March 2007.

For more information about treatment with Xelevia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Xelevia : EPAR - Summary for the public

English (EN) (62.28 KB - PDF)

**First published:** 07/12/2009

**Last updated:** 21/09/2012

[View](/en/documents/overview/xelevia-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-845)

български (BG) (103.35 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/bg/documents/overview/xelevia-epar-summary-public_bg.pdf)

español (ES) (142.28 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/es/documents/overview/xelevia-epar-summary-public_es.pdf)

čeština (CS) (153.19 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/cs/documents/overview/xelevia-epar-summary-public_cs.pdf)

dansk (DA) (65.02 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/da/documents/overview/xelevia-epar-summary-public_da.pdf)

Deutsch (DE) (126.6 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/de/documents/overview/xelevia-epar-summary-public_de.pdf)

eesti keel (ET) (84.48 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/et/documents/overview/xelevia-epar-summary-public_et.pdf)

ελληνικά (EL) (166.26 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/el/documents/overview/xelevia-epar-summary-public_el.pdf)

français (FR) (124.07 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/fr/documents/overview/xelevia-epar-summary-public_fr.pdf)

italiano (IT) (125.1 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/it/documents/overview/xelevia-epar-summary-public_it.pdf)

latviešu valoda (LV) (92.8 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/lv/documents/overview/xelevia-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (149.4 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/lt/documents/overview/xelevia-epar-summary-public_lt.pdf)

magyar (HU) (86.93 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/hu/documents/overview/xelevia-epar-summary-public_hu.pdf)

Malti (MT) (91.15 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/mt/documents/overview/xelevia-epar-summary-public_mt.pdf)

Nederlands (NL) (63.27 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/nl/documents/overview/xelevia-epar-summary-public_nl.pdf)

polski (PL) (151.91 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/pl/documents/overview/xelevia-epar-summary-public_pl.pdf)

português (PT) (62.66 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/pt/documents/overview/xelevia-epar-summary-public_pt.pdf)

română (RO) (90.43 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/ro/documents/overview/xelevia-epar-summary-public_ro.pdf)

slovenčina (SK) (150.02 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/sk/documents/overview/xelevia-epar-summary-public_sk.pdf)

slovenščina (SL) (147.33 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/sl/documents/overview/xelevia-epar-summary-public_sl.pdf)

Suomi (FI) (124.41 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/fi/documents/overview/xelevia-epar-summary-public_fi.pdf)

svenska (SV) (144.58 KB - PDF)

**First published:**

07/12/2009

**Last updated:**

21/09/2012

[View](/sv/documents/overview/xelevia-epar-summary-public_sv.pdf)

Xelevia : EPAR - Risk management plan summary

English (EN) (206.62 KB - PDF)

**First published:** 30/06/2022

[View](/en/documents/rmp-summary/xelevia-epar-risk-management-plan-summary_en.pdf)

## Product information

Xelevia : EPAR - Product Information

English (EN) (340.36 KB - PDF)

**First published:** 08/12/2009

**Last updated:** 01/12/2025

[View](/en/documents/product-information/xelevia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-999)

български (BG) (324.44 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/bg/documents/product-information/xelevia-epar-product-information_bg.pdf)

español (ES) (376.08 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/es/documents/product-information/xelevia-epar-product-information_es.pdf)

čeština (CS) (360.36 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/cs/documents/product-information/xelevia-epar-product-information_cs.pdf)

dansk (DA) (358.21 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/da/documents/product-information/xelevia-epar-product-information_da.pdf)

Deutsch (DE) (387.18 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/de/documents/product-information/xelevia-epar-product-information_de.pdf)

eesti keel (ET) (360.64 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/et/documents/product-information/xelevia-epar-product-information_et.pdf)

ελληνικά (EL) (337.98 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/el/documents/product-information/xelevia-epar-product-information_el.pdf)

français (FR) (404.76 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/fr/documents/product-information/xelevia-epar-product-information_fr.pdf)

hrvatski (HR) (363.03 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/hr/documents/product-information/xelevia-epar-product-information_hr.pdf)

íslenska (IS) (359.03 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/is/documents/product-information/xelevia-epar-product-information_is.pdf)

italiano (IT) (384.42 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/it/documents/product-information/xelevia-epar-product-information_it.pdf)

latviešu valoda (LV) (333.6 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/lv/documents/product-information/xelevia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (355.09 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/lt/documents/product-information/xelevia-epar-product-information_lt.pdf)

magyar (HU) (385.93 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/hu/documents/product-information/xelevia-epar-product-information_hu.pdf)

Malti (MT) (375.26 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/mt/documents/product-information/xelevia-epar-product-information_mt.pdf)

Nederlands (NL) (373.72 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/nl/documents/product-information/xelevia-epar-product-information_nl.pdf)

norsk (NO) (355.04 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/no/documents/product-information/xelevia-epar-product-information_no.pdf)

polski (PL) (381.92 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/pl/documents/product-information/xelevia-epar-product-information_pl.pdf)

português (PT) (384.44 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/pt/documents/product-information/xelevia-epar-product-information_pt.pdf)

română (RO) (359.73 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/ro/documents/product-information/xelevia-epar-product-information_ro.pdf)

slovenčina (SK) (376.18 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/sk/documents/product-information/xelevia-epar-product-information_sk.pdf)

slovenščina (SL) (371.54 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/sl/documents/product-information/xelevia-epar-product-information_sl.pdf)

Suomi (FI) (377.19 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/fi/documents/product-information/xelevia-epar-product-information_fi.pdf)

svenska (SV) (368.16 KB - PDF)

**First published:**

08/12/2009

**Last updated:**

01/12/2025

[View](/sv/documents/product-information/xelevia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000314048 24/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xelevia : EPAR - All Authorised presentations

English (EN) (21.39 KB - PDF)

**First published:** 26/03/2007

**Last updated:** 27/03/2014

[View](/en/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-599)

български (BG) (43.59 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/bg/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_bg.pdf)

español (ES) (22.34 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/es/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/cs/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.6 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/da/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (22.17 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/de/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (22.11 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/et/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.39 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/el/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_el.pdf)

français (FR) (20.58 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/fr/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.19 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/hr/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.27 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/is/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.33 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/it/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (67.98 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/lv/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (74.03 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/lt/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (56.01 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/hu/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.22 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/mt/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.49 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/nl/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.43 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/no/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.9 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/pl/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.98 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/pt/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.92 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/ro/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.87 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/sk/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.84 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/sl/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (20.53 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/fi/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (20.84 KB - PDF)

**First published:**

26/03/2007

**Last updated:**

27/03/2014

[View](/sv/documents/all-authorised-presentations/xelevia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xelevia Active substance sitagliptin International non-proprietary name (INN) or common name sitagliptin Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BH01

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:

- as monotherapy:
    - in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;
- as dual oral therapy in combination with:
    - metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;
    - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;
    - a peroxisome proliferator-activated receptor gamma (PPAR?) agonist (i.e. a thiazolidinedione) when use of a PPAR? agonist is appropriate and when diet and exercise plus the PPAR? agonist alone do not provide adequate glycaemic control;
- as triple oral therapy in combination with:
    - a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;
    - a PPAR? agonist and metformin when use of a PPAR? agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

## Authorisation details

EMA product number EMEA/H/C/000762 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Opinion adopted 14/11/2023 Marketing authorisation issued 21/03/2007 Revision 42

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xelevia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.75 KB - PDF)

**First published:** 01/12/2025

[View](/en/documents/procedural-steps-after/xelevia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Xelevia : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (278.71 KB - PDF)

**First published:** 08/12/2009

**Last updated:** 01/12/2025

[View](/en/documents/procedural-steps-after/xelevia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Xelevia-PAM-0000244508 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-1838618

English (EN) (2.2 MB - PDF)

**First published:** 27/06/2025

[View](/en/documents/variation-report/xelevia-pam-0000244508-epar-assessment-report_en.pdf)

Xelevia : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMEA/H/C/000762/IB/0073

English (EN) (92.5 KB - PDF)

**First published:** 24/02/2021

[View](/en/documents/pip-compliance/xelevia-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Xelevia : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan (IB-73)

Reference Number: EMEA/H/C/000762/IB/0073

English (EN) (92.5 KB - PDF)

**First published:** 19/11/2020

[View](/en/documents/pip-compliance/xelevia-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan-ib-73_en.pdf)

Xelevia-H-C-PSUSA-00002711-201708 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/423578/2018

English (EN) (68.32 KB - PDF)

**First published:** 22/06/2018

**Last updated:** 22/06/2018

[View](/en/documents/scientific-conclusion/xelevia-h-c-psusa-00002711-201708-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xelevia-H-C-PSUSA-00002711-201408 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/304624/2015

English (EN) (78.87 KB - PDF)

**First published:** 13/07/2015

**Last updated:** 13/07/2015

[View](/en/documents/scientific-conclusion/xelevia-h-c-psusa-00002711-201408-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xelevia-H-C-762-P46-0029 : EPAR - Assessment Report

Adopted

Reference Number: EMA/191361/2013

English (EN) (1.01 MB - PDF)

**First published:** 27/03/2013

**Last updated:** 27/03/2013

[View](/en/documents/variation-report/xelevia-h-c-762-p46-0029-epar-assessment-report_en.pdf)

Xelevia-H-C-762-II-0012 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/767819/2009

English (EN) (438.61 KB - PDF)

**First published:** 08/12/2009

**Last updated:** 08/12/2009

[View](/en/documents/variation-report/xelevia-h-c-762-ii-0012-epar-assessment-report-variation_en.pdf)

Xelevia-H-C-762-II-0009 : EPAR - Assessment Report - Variation

English (EN) (388.51 KB - PDF)

**First published:** 09/10/2009

**Last updated:** 09/10/2009

[View](/en/documents/variation-report/xelevia-h-c-762-ii-0009-epar-assessment-report-variation_en.pdf)

CHMP post authorisation summary of positive opinion for Xelivia on 24 September 2009

Adopted

Reference Number: EMEA/CHMP/546145/2009

English (EN) (36.21 KB - PDF)

**First published:** 25/09/2009

**Last updated:** 25/09/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xelivia-24-september-2009_en.pdf)

Xelevia-H-C-762-II-0007 : EPAR - Assessment Report - Variation

English (EN) (908.95 KB - PDF)

**First published:** 06/07/2009

**Last updated:** 06/07/2009

[View](/en/documents/variation-report/xelevia-h-c-762-ii-0007-epar-assessment-report-variation_en.pdf)

CHMP post authorisation summary of positive opinion for Xelivia on 25 June 2009

Adopted

Reference Number: EMEA/CHMP/369153/2009

English (EN) (35.86 KB - PDF)

**First published:** 25/06/2009

**Last updated:** 25/06/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xelivia-25-june-2009_en.pdf)

CHMP post authorisation summary of positive opinion for Xelivia on 23 April 2009

Adopted

Reference Number: EMEA/CHMP/240341/2009

English (EN) (34.51 KB - PDF)

**First published:** 23/04/2009

**Last updated:** 23/04/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-xelivia-23-april-2009_en.pdf)

Xelevia-H-C-762-II-0002 : EPAR - Assessment Report - Variation

English (EN) (257.36 KB - PDF)

**First published:** 29/05/2008

**Last updated:** 29/05/2008

[View](/en/documents/variation-report/xelevia-h-c-762-ii-0002-epar-assessment-report-variation_en.pdf)

Committee for medicinal products for human use  post authorisation summary of positive opinion for  Xelivia on 15 November 2007

Reference Number: EMEA/CHMP/536624/2007

English (EN) (38.65 KB - PDF)

**First published:** 20/12/2007

**Last updated:** 20/12/2007

[View](/en/documents/smop/committee-medicinal-products-human-use-post-authorisation-summary-positive-opinion-xelivia-15-november-2007_en.pdf)

## Initial marketing authorisation documents

Xelevia : EPAR - Procedural steps taken before authorisation

English (EN) (21.14 KB - PDF)

**First published:** 26/03/2007

**Last updated:** 26/03/2007

[View](/en/documents/procedural-steps/xelevia-epar-procedural-steps-taken-authorisation_en.pdf)

Xelevia : EPAR - Scientific Discussion

English (EN) (475.92 KB - PDF)

**First published:** 26/03/2007

**Last updated:** 26/03/2007

[View](/en/documents/scientific-discussion/xelevia-epar-scientific-discussion_en.pdf)

#### News on Xelevia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Investigation into GLP-1-based diabetes therapies concluded](/en/news/investigation-glp-1-based-diabetes-therapies-concluded) 26/07/2013

[European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes](/en/news/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes) 26/03/2013

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Xelevia : EPAR - Product information - tracked changes

English (EN) (308 KB - DOC)

**First published:** 01/12/2025

[View](/en/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_en.doc)

[Other languages (24)](#file-language-dropdown-428)

български (BG) (412 KB - DOC)

**First published:**

01/12/2025

[View](/bg/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_bg.doc)

español (ES) (343 KB - DOC)

**First published:**

01/12/2025

[View](/es/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_es.doc)

čeština (CS) (370.5 KB - DOC)

**First published:**

01/12/2025

[View](/cs/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (324.5 KB - DOC)

**First published:**

01/12/2025

[View](/da/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (293.5 KB - DOC)

**First published:**

01/12/2025

[View](/de/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_de.doc)

eesti keel (ET) (115.85 KB - DOCX)

**First published:**

01/12/2025

[View](/et/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (418.5 KB - DOC)

**First published:**

01/12/2025

[View](/el/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_el.doc)

français (FR) (318.5 KB - DOC)

**First published:**

01/12/2025

[View](/fr/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_fr.doc)

hrvatski (HR) (411.5 KB - DOC)

**First published:**

01/12/2025

[View](/hr/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_hr.doc)

íslenska (IS) (321.5 KB - DOC)

**First published:**

01/12/2025

[View](/is/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_is.doc)

italiano (IT) (115.27 KB - DOCX)

**First published:**

01/12/2025

[View](/it/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (414 KB - DOC)

**First published:**

01/12/2025

[View](/lv/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_lv.doc)

lietuvių kalba (LT) (407 KB - DOC)

**First published:**

01/12/2025

[View](/lt/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (397 KB - DOC)

**First published:**

01/12/2025

[View](/hu/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (142.85 KB - DOCX)

**First published:**

01/12/2025

[View](/mt/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (117.73 KB - DOCX)

**First published:**

01/12/2025

[View](/nl/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (331.5 KB - DOC)

**First published:**

01/12/2025

[View](/no/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_no.doc)

polski (PL) (416 KB - DOC)

**First published:**

01/12/2025

[View](/pl/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_pl.doc)

português (PT) (311 KB - DOC)

**First published:**

01/12/2025

[View](/pt/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_pt.doc)

română (RO) (133.71 KB - DOCX)

**First published:**

01/12/2025

[View](/ro/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (131.34 KB - DOCX)

**First published:**

01/12/2025

[View](/sk/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (461.5 KB - DOC)

**First published:**

01/12/2025

[View](/sl/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (364 KB - DOC)

**First published:**

01/12/2025

[View](/fi/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (124.56 KB - DOCX)

**First published:**

01/12/2025

[View](/sv/documents/product-information-tracked-changes/xelevia-epar-product-information-tracked-changes_sv.docx)

#### More information on Xelevia

- [EMEA-000471-PIP01-08-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000471-pip01-08-m02)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 01/12/2025

## Share this page

[Back to top](#main-content)